Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patents Face 'Real Threat' From Inter Partes Review; PTAB Open To Change

Executive Summary

Pfizer attorney says brand-name drug companies no longer can rely on the outcome of ANDA litigation to predict date of generic competition; PTAB chief judge observes that there is 'opportunity to get some more certainty for patent owners.'

Advertisement

Related Content

Pfizer Keeps IPR Winning Streak; Court Affirms Ruling On Tygacil Patent
Supreme Court Upholds IPR Standard Making Patent Invalidation Easier; Will Congress Reverse?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel